Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Sellas Life Sciences Group Inc (NQ: SLS)
3.370 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 4:00 PM EDT, Aug 11, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 3.370
Bid (Size) 3.350 (10)
Ask (Size) 3.620 (3)
Prev. Close 3.370
Today's Range 3.370 - 3.370
52wk Range 0.1100 - 6.880
Shares Outstanding 6,655,155
Dividend Yield N/A
Performance
YTD
-17.40%
-17.40%
1 Month
+19.08%
+19.08%
3 Month
+14.24%
+14.24%
6 Month
+22.55%
+22.55%
1 Year
+1980.25%
+1980.25%
Top News
More News
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market
Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study Read More
from GlobeNewswire News Releases
Targeting The National Cancer Institute's #1- Ranked Cancer Antigen: SELLAS' Most Advanced Immunotherapy in Pivotal Phase 3 Study in AML and in Phase 1/2 Studies in Combination With PD1
from Newsfile Corp News Releases
More News
Read More
SELLAS to Host Virtual Annual Meeting of Stockholders
from GlobeNewswire News Releases
Looking For Penny Stocks To Buy? Here’s What Analysts Think
from Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
SELLAS Establishes Independent Data Monitoring Committee of Leading Clinical and Biostatistics Experts for Pivotal Phase 3 REGAL Clinical Trial
from GlobeNewswire News Releases
SELLAS Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
from GlobeNewswire News Releases
SELLAS to Present at UBS Virtual Global Healthcare Conference
from GlobeNewswire News Releases
SELLAS Releases Annual Letter to Shareholders
from GlobeNewswire News Releases
SELLAS Appoints Steering Committee of Leading Acute Myeloid Leukemia Experts for Its Ongoing Phase 3 REGAL Clinical Trial in AML
from GlobeNewswire News Releases
SELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast from Phase 2 VADIS Study
from GlobeNewswire News Releases
SELLAS Life Sciences Reports Full Year 2019 Financial Results and Provides Business Update
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.